Fresenius SE & Co. KGaA (ETR: FRE)
Germany
· Delayed Price · Currency is EUR | Market Cap | 18.76B |
| Revenue (ttm) | 22.63B |
| Net Income (ttm) | -1.12B |
| Shares Out | 563.24M |
| EPS (ttm) | -1.98 |
| PE Ratio | 26.01 |
| Forward PE | 10.21 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 628,678 |
| Open | 33.27 |
| Previous Close | 33.29 |
| Day's Range | 33.19 - 33.39 |
| 52-Week Range | 23.93 - 35.03 |
| Beta | 1.07 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 6, 2024 |
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, dialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patie... [Read more]
Financial Performance
Financial StatementsNews
Fresenius: Showing Signs Of Recovery, We Have Dawn
Fresenius is showing early signs of recovery, with improved profitability and simplified structure. Read why FSNUF stock remains a Buy for long-term investors.
Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2024 Earnings Conference Call July 31, 2024 7:30 AM ET Company Participants Markus Georgi - Head of Investor Relations. Michael Sen - Chief Executive Officer S...
Fresenius: It's Darkest Before The Dawn
Fresenius, a German healthcare company, has the potential for significant growth and a near-term turnaround. The company is in the midst of a restructuring and has met its revenue and earnings targets...
Fresenius SE: Hoping For The Turnaround In 2024
Fresenius reported mediocre results and suspended the dividend this year, but management is optimistic for fiscal 2024. The company will focus on reducing debt levels in 2024 and the deconsolidation o...
Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q4 2023 Earnings Call Transcript
Healthcare group Fresenius tops Q4 operating profit expectations
Fresenius reported a bigger-than-expected 13% jump in fourth-quarter operating profit on Wednesday, citing good earnings development across its businesses and progress in the operational turnaround at...
Fresenius perfectly positioned to combat health inequality, says CEO
Michael Sen, CEO at Fresenius, explains what the company is doing to help close the health care gap.
Fresenius SE & Co. KGaA (FSNUF) Q2 2023 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2023 Earnings Conference Call November 2, 2023 12:00 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Michael Sen - Chief...
Fresenius to assess whether state aid impacts bonus, dividend payouts
German healthcare group Fresenius said it was examining whether the state aid it received to help offset high energy costs at its hospitals business would bar it from making management bonus and divid...
Fresenius SE Probably Found Its Bottom
Fresenius SE outperformed the S&P 500 in the last few quarters and could have found its temporary bottom. While the quarterly results are still not great, Fresenius Kabi is expected to grow with a hig...
Fresenius: 90%+ Upside At This Time
Fresenius, a German healthcare company, is highlighted as a promising investment due to its global presence, market leadership, and potential for significant growth in the coming years. Despite underp...
Fresenius launches biosimilar version of AbbVie's Humira at 5% discount
The generic drug unit of Germany's Fresenius said on Monday the price for Idacio, its copycat version of Abbvie's top-selling rheumatoid arthritis drug, will be at a 5% discount to Humira's list price...
Fresenius: Still Struggling, Still Undervalued
Fresenius: Still Struggling, Still Undervalued.
Fresenius SE & Co. KGaA (FSNUF) Q4 2022 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q4 2022 Results Conference Call February 22, 2023 7:30 AM ET Company Participants Markus Georgi - Senior Vice President-Investor Relations Michael Sen - Chief Exe...
Germany's Fresenius to simplify structure, flags potential profit fall
German healthcare group Fresenius SE will slash costs and proceed with plans to cede strategic control over struggling dialysis group Fresenius Medical Care (FMC) as its new CEO seeks to simplify the ...
Fresenius: One-Off Special Situation Opportunity To Buy
Over the last six months, Fresenius has seen the exit of its CEO, increasing activist exposure, and is reviewing the deconsolidation of its largest subsidiary Fresenius Medical Care. We view this deco...
Fresenius: Maximum Pessimism Reached, Potential Triple-Digit 3-Year Rate Of Return
I've been buying Fresenius in small portions and adding to my position again and again over the past year. It's now more than 3% of my portfolio. While this company remains a long-term turnaround play...
Fresenius SE: A Buy After Quarterly Results
Fresenius SE is reporting mediocre results once again with Fresenius Medical Care struggling due to labor shortage and macroeconomic challenges. While Fresenius Medical Care and Fresenius Kabi are str...
Fresenius SE & Co. KGaA (FSNUF) Q3 2022 Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q3 2022 Earnings Conference Call October 31, 2022 8:30 AM ET Company Participants Markus Georgi – Senior Vice President-Investor Relations Michael Sen – Chief Exe...
Fresenius - No One Likes A Contrarian During A Downturn
I've received plenty of inquiries with regards to Fresenius and its somewhat terrible performance YTD so far. Readers are asking if I'm "out" the company, or if I continue to believe that this company...
Fresenius SE CEO to quit after earnings outlook sours
FRANKFURT (Reuters) -Fresenius SE said its long-serving Chief Executive Stephan Sturm would quit, to be replaced by the head of its drugs unit, after the diversified group's earnings were hit followin...
Fresenius: Too Cheap, Measured By Sum-Of-The-Parts
The shares of Fresenius, one of the world's largest healthcare groups, have been in a downward and then a sideways trend since 2017. Corona pandemic has been a major challenge, especially for its subs...
Fresenius SE & Co. KGaA (FSNUF) CEO Stephan Sturm on Q2 2022 Results - Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q2 2022 Earnings Conference Call July 28, 2022 7:30 AM ET Company Participants Markus Georgi - Senior Vice President of Investor Relations Stephan Sturm - Preside...
Fresenius: Revisiting The Thesis - Still A Buy
We'll take a look at Fresenius in order to determine if the company still represents a good investment opportunity. Given a recent share price weakness, it's not strange that some investors are wonder...
Fresenius SE & Co. KGaA (FSNUF) CEO Stephan Sturm on Q1 2022 Results - Earnings Call Transcript
Fresenius SE & Co. KGaA (OTCPK:FSNUF) Q1 2022 Earnings Conference Call May 4, 2022 7:30 AM ET Company Participants Stephan Sturm – President & Chief Executive Officer Rachel Empey – Chief Financial Of...